Cinclus Pharma Holding ABFRA:J8P -1.23%6 EBITDA Margin % is -896.35% as of Mar. 2026. GuruFocus rates FRA:J8P with a GF Score™ of 6/100. The stock has 3 warning signs investors should review. Among 955 Drug Manufacturers companies, Cinclus Pharma Holding AB ranks worse than 95.08% on this metric.
Cinclus Pharma Holding AB (FRA:J8P) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Cinclus Pharma Holding AB EBITDA Margin % Related Terms
Cinclus Pharma Holding AB EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cinclus Pharma Holding AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cinclus Pharma Holding AB EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cinclus Pharma Holding AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Cinclus Pharma Holding AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cinclus Pharma Holding AB (FRA:J8P) has a EBITDA Margin % of -896.35% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cinclus Pharma Holding AB and its competitors. According to the industry distribution chart, Cinclus Pharma Holding AB ranks #908 out of 955 companies in the Drug Manufacturers industry, placing it in the top 95.1%.
Is Cinclus Pharma Holding AB's EBITDA Margin % too high?
Cinclus Pharma Holding AB's current EBITDA Margin % is -896.35%. Based on the distribution chart, Cinclus Pharma Holding AB ranks #908 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cinclus Pharma Holding AB has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Cinclus Pharma Holding AB's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cinclus Pharma Holding AB ranks #908 out of 955 companies for EBITDA Margin %. This places Cinclus Pharma Holding AB in the lower half of its industry. The industry median EBITDA Margin % is 12.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cinclus Pharma Holding AB and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cinclus Pharma Holding AB's current EBITDA Margin % is -896.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cinclus Pharma Holding AB stock overvalued right now?
Cinclus Pharma Holding AB (FRA:J8P) has a current EBITDA Margin % of -896.35%. The current EBITDA Margin % is -896.35%. Cinclus Pharma Holding AB's overall GF Score™ is 6/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Cinclus Pharma Holding AB (FRA:J8P), the current EBITDA Margin % is -896.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cinclus Pharma Holding AB is a Swedish clinical-stage pharmaceutical company focused on developing small-molecule treatments for gastric acid-related diseases. Its candidate, linaprazan glurate, is being developed for the treatment of severe gastroesophageal reflux disease, including erosive forms. The company is also developing a dual therapy treatment with an antibiotic targeting Helicobacter pylori, a bacterium found in the gastric and duodenal mucosa. Its primary target population consists of patients with severe erosive gastroesophageal reflux disease, where current treatment options are limited. It operates in Switzerland, Sweden, and the Czech Republic, with the majority of revenue from the Czech Republic.
6GF Score
Get the complete analysis for FRA:J8P
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:J8P has been successfully added to your 
